Aura Biosciences, Inc. 8-K

What Happened
Aura Biosciences, Inc. (AURA) announced its financial results for the fourth quarter and the year ended December 31, 2025 in a press release filed on March 30, 2026. The company furnished the press release as Exhibit 99.1 to its Current Report on Form 8-K (Item 2.02) and also filed an updated corporate presentation for investor meetings as Exhibit 99.2 (Item 8.01). The Form 8-K was signed by President and Chief Executive Officer Elisabet de los Pinos on March 30, 2026.

Key Details

• Filing date: March 30, 2026 (Current Report on Form 8-K).
• Financials covered: fourth quarter and full year ended December 31, 2025 (press release filed as Exhibit 99.1).
• Investor materials: updated corporate presentation filed as Exhibit 99.2 for use with investors and analysts.
• Authorized signature: Elisabet de los Pinos, President & CEO, signed the filing.

Why It Matters
The 8-K provides the company’s latest quarterly results and year-end financial information—key data for assessing recent revenue, earnings trends, and financial condition. The updated corporate presentation may include management’s latest messaging to investors and any operational or strategic highlights. Retail investors should review the attached press release and presentation (Exhibits 99.1 and 99.2) for the detailed numbers, discussion of results, and any forward-looking statements or guidance included by management.